Mayo Clinic Comprehensive Cancer Center
@MayoCancerCare
Followers
14K
Following
4K
Media
9K
Statuses
26K
Personalized #CancerTreatment + leading-edge #CancerResearch and #ClinicalTrials = unparalleled #CancerCare. https://t.co/g8MpWrFymC
Arizona, Florida and Minnesota
Joined March 2014
Oncologist Tufia C. Haddad, M.D., with a specialty interest in precision medicine in #breastcancer, is presenting today at #SABCS25 on big data to solve big problems. Educational Session 15: Real Impact with Artificial Intelligence 2:30 – 4:15 p.m. CST Stars at Night 3-4
0
1
3
Congratulations to our AI team for winning TWO #VIBEsummit awards for their work developing tools detect prostate cancer recurrence and reduce provider burden with automated daily summaries and trial matching. So proud of this incredible team! @MayoRadOnc @MayoCancerCare
1
2
16
Because of his contributions, patients now benefit from more accurate risk-assessment tools that guide screening, prevention strategies and clinical decision-making for patients worldwide. Congratulations, Dr. Couch. 🧵(4/4) Read the news release. https://t.co/fGQU2t3d7k.
komen.org
Discover howKomen honors five trailblazers in breast cancer research and advocacy for their groundbreaking work in the breast cancer space.
0
0
0
He also demonstrated that expanding #genetictesting to women up to age 65 improves the detection of those at higher risk. And, by characterizing risk genes across populations, he helped enable earlier and more personalized screening strategies. 🧵(3/4)
mayo.edu
Learn more about services at Mayo Clinic.
1
0
0
His research showed that certain gene alterations present at birth can increase a person’s risk of #breastcancer and brought clarity to previously misunderstood BRCA1 and BRCA2 gene mutations. 🧵(2/4)
1
0
0
Our Fergus Couch, Ph.D., professor of laboratory medicine and pathology, was awarded the Susan G. Komen Brinker Award for Scientific Distinction in Basic Science. Dr. Couch has played a central role in understanding genetic mutations linked to #breastcancer. 🧵(1/4)
1
0
0
Medical oncologist Tony B. D'Assoro, M.D., Ph.D., presents abstract PS2-11-08: Stemness-targeted therapies to enhance the efficacy of AURKA inhibitors in endocrine resistant ER+ #breastcancer. #SABCS25
0
0
0
Mitra Abdollahi Neisani shares abstract PS2-07-09: Epigenetic Imprinting as a Novel Precision Biomarker for Early #BreastCancer and Precancer Diagnosis and Detection. #SABCS25
1
0
0
Medical oncologist Pooja P. Advani, M.D., presents abstract PS2-12-07: Metabolic and immune reprogramming via SCD1 inhibition enhances chemo-immunotherapy response in TNBC. #breastcancer #SABCS25
1
0
0
Predoctoral student Anna Detry presents abstract PS2-11-01: Lmtk2: a novel driver of endocrine resistance in ER+ #breastcancer.
1
0
0
Medical oncologist Saranya Chumsri, M.D., shares abstract PS2-09-08: Tertiary lymphoid structure (TLS)-related gene expression and outcomes in HER2-Positive (HER2+) #breastcancer in the Real-World Database. #SABCS25
1
0
1
Medical Oncologist Karthik Giridhar, M.D., presents abstract PS2-07-17: Characterizing circulating tumor cell (CTC) enumeration and phenotypic profiling in blood with synchronously obtained tissue in metastatic #breastcancer (MBC) in TBCRC /AURORA US. #SABCS25
1
0
0
Resident Yajur Arya presents abstract PS2-06-02: Real-world outcomes comparing zoledronic acid and pamidronate in patients with metastatic #breastcancer with bone metastases: A propensity score matched analysis from a global federated health research network.
1
0
0
Medical oncologist, Siddhartha Yadav, M.D., shares abstract PS2-02-08: Real-world PARP inhibitor use and clinical outcomes in US patients with HER2-negative metastatic #breastcancer. #SABCS25
1
0
0
At #SABCS25 Poster Session 2, our researchers will be presenting nine abstracts. Follow along as we share the details of their innovative and transformative work in #breastcancer. 5:00 - 6:30 p.m. CST Exhibit Hall https://t.co/SbuBS59jvq
sabcs.org
Details coming soon.
1
0
2
At today's #SABCS25, renowned scientist Dr. Fergus Couch is presenting his research on the interpretation of inherited alterations in high and moderate risk genes in #breastcancer. 2:30 - 4:15 p.m. CST 221 ABC Education Session 9
sabcs.org
0
0
0
Dr. Jewel (Juliana) Kling has dedicated her career to studying and improving care related to menopause and female sexual health. In this session at #SABCS25 she addresses symptoms related to Genitourinary Syndrome of Menopause with low dose estrogens in women after #breastcancer.
Balancing Act: Hormone Replacement Therapy in Breast Cancer Care— Maryam Lustberg, Juliana Kling, @LisaLarkinMD, & advocate Thelma P. Brown addressed this topic in an #SABCS25 educational session moderated by Tana Sanft. @maryam_lustberg @DrJewelKling @tperrybrown @tarasanftmd
0
0
2
Patient and public involvement and engagement (PPIE) is well established in clinical settings, but less well defined in laboratory settings. Here our researchers propose a framework for embedding PPIE ambassadors into basic #CancerResearch pipelines. ⬇️
Advocating for #patient #partners to guide meaningful research Wonderful piece written by @shreya_gandhi2 @MansouriSheila published today @NatureRevCancer Welcome partnerships with @MayoClinic @MayoClinicNeuro @MayoCancerCare
0
1
5
Most patients with drug-resistant, true extramedullary #myeloma had a response with talquetamab plus teclistamab. The incidence of adverse events of grade 3 or above was high and was consistent with previous observations for each agent as monotherapy. Read the paper. ⬇️
Proud of my friend and colleague @MayoClinic @MayoCancerCare for leading this trial and being first author on the @NEJM paper. Congrats Shaji, @myelomaMD
https://t.co/8u4zDekJam
0
0
1